Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | Decision Base | US/EU | 2014
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive)…
Prostate Cancer (First-Line – Chemotherapy-Naive – Metastatic Castrate-Resistant) | DecisionBase | US/EU | 2014
As Abiraterone and Enzalutamide Gain Traction in the Market, What Key Attributes Do Oncologists and Payers Say Will Differentiate Emerging Therapies? The first-line (chemotherapy-naive)…
The Impact of LATAM – Payer Policy on Prescribing in Non-Hodgkin’s Lymphoma and Multiple Myeloma | Physician & Payer Forum | Brazil and Mexico | 2014
Improved patient access to specialized medical care and increased use of target therapies in oncology are expanding the multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL) markets in Brazil…
Type 2 Diabetes Inadequately Controlled with Diet and Exercise (First-Line Drug Treatment) | Decision Base | US/EU | 2014
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
Type 2 Diabetes Inadequately Controlled with Diet and Exercise (First-Line Drug Treatment) | Decision Base | US/EU | 2014
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
Patient Access to High-Cost Therapies for CML in China: How Are Payers and Physicians Shaping This Crowded and Changing Market? | Physician & Payer Forum | China | 2014
Chronic myeloid leukemia (CML) in China presents a huge challenge for healthcare providers but is a considerable opportunity for drug manufacturers. The launch of Novartis’s Glivec (imatinib), an…
Convenient Once-daily Fixed-dose Combination Inhaler and Late-Stage Emerging Biologics in Asthma: How Will U.S. Payers and Prescribers Manage Different Segments of the Asthma Market? | Physician & Payer Forum | US | 2014
Asthma is a chronic inflammatory disorder of the airways leading to recurring episodes of wheezing, breathlessness, chest tightness, and coughing, with episodes characterized by airflow obstruction…
